Cannabis
Quebec Cannabis Society – SQDC Registers Record Profits in Q2
The SQDC achieved $173.7M in sales for Q2, a 26% increase, selling 34,675kg of cannabis. Net sales rose 15% to $29.4M, with $73.3M in taxes benefiting Quebec. Average cannabis prices fell to $5.76/gram, reflecting demand for affordable options. Focused on refining consumer experience, SQDC opened its 100th store while enhancing its retail strategies.
The Société québécoise du cannabis (SQDC) recorded unprecedented revenues in the second quarter of the 2024-2025 fiscal year, partly thanks to the adaptation of its product offering to meet consumer demands.
SQDC: Growth in sales and transactions
During the quarter, the SQDC achieved total sales of $173.7 million (€116 million), which represents a substantial increase of 26% compared to the $151.7 million recorded during the same period last year. The quantity of cannabis sold also jumped, reaching 34,675 kilograms, compared to 27,498 kilograms in the second quarter of the 2023-2024 fiscal year.
Net sales reached $29.4 million , an increase of 15% over the prior year’s $24.9 million. This performance coincided with an increase in consumer transactions, which totaled $ 4.4 million, a significant increase over the $3.6 million recorded in the prior year quarter.
The SQDC’s activities generated substantial revenue for the provincial government. During the quarter, Quebec received $43.9 million in cannabis taxes , while the federal government collected $17.5 million. In total, cannabis sales contributed $ 73.3 million to Quebec’s revenue. These funds are reinvested in initiatives such as cannabis research and prevention programs.
Towards affordable products
The average selling price of cannabis fell to $5.76 per gram , compared to $6.34 per gram in the same quarter of 2023. This decline reflects a notable shift in consumer demand toward less expensive products and concentrates , which are generally priced lower than other categories. Despite this trend, the agency has managed to maintain profitability by increasing its sales volume and refining its offerings to meet diverse consumer preferences.
In the second quarter, the SQDC opened two new branches, including the 100th in Richelieu, Montérégie, and another in Donnacona. The SQDC has not opted for an aggressive expansion of its stores, as is the case in Ontario , but instead focuses on improving the consumer experience in its existing stores. According to Suzanne Bergeron, President and CEO of the SQDC, the agency has used six years of consumer data to better understand their preferences and refine its retail strategies.
“We’re starting to get a good amount of data on consumer preferences, what they like and what they don’t like, [as well as] what keeps them in the illicit market versus what they’re coming to the SQDC for,” Bergeron said in an interview with StratCann.
“Knowing that, we’re able to refine the strategy on how we’re going to tailor our stores so they feel welcome when they come in.”
__
(Featured image by Terrance Barksdale via Pexels)
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in NEWSWEED. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us
-
Fintech1 week ago
Deutsche Bank Develops Layer 2 for Ethereum – With Extras for Authorities
-
Biotech2 weeks ago
Quirónsalud and Roche Farma Sign an Agreement to Promote Healthcare Innovation and Research
-
Business6 days ago
TopRanked.io Weekly Affiliate Digest: What’s Hot in Affiliate Marketing [1xBet Partner Program Review]
-
Biotech1 week ago
Novo Nordisk: Ozempic Gets Positive Evaluation for Kidney Treatment